Request for Generic Risdiplam Accessibility Under Rare Disease Policy for Spinal Muscular Atrophy Patients

Patients have submitted an appeal to the Prime Minister, emphasizing the urgent need for timely access to Risdiplam, a generic medication now manufactured in India. This treatment is crucial for individuals suffering from spinal muscular atrophy (SMA), a life-limiting neuromuscular condition that can lead to significant health complications if not addressed promptly.

The availability of generic Risdiplam is seen as a significant advancement, as it could potentially lower treatment costs and increase accessibility for many patients across the country. Delays in receiving treatment can lead to irreversible deterioration in health, highlighting the importance of immediate access to effective therapies for SMA.

Spinal muscular atrophy affects motor neurons in the spinal cord, leading to muscle weakness and atrophy. Approximately 1 in every 10,000 live births in India is diagnosed with this condition, and the demand for affordable, timely treatment is critical. The appeal aims to raise awareness about the urgency of this issue and to advocate for policies that facilitate better access to essential medications for patients in need.